Explore Stanford technologies available for licensing:

The Problem: Chronic pain is best treated with a 'whole-person' approach that include behavioral/psychological approaches to pain self-management.

Researchers at Stanford University have identified a small molecule tryptase inhibitor for treatment of severe allergies. Mast cells are a part of the innate and adaptive immune response. Mast Cell activation results in release of granules containing tryptases.

Exhausted T cells are T cells that become dysfunctional after a period of time and play a role in reduced efficacy of T cell targeted immunotherapies.

Stanford researchers in the Heilshorn lab have developed injectable, cell-compatible hydrogels with tunable release of therapeutic cargo.

Stanford researchers in the WE3 and S3 Labs developed a cloud-based computation and predictive control platform for wastewater treatment facilities energy storage and energy generation. Wastewater treatment is energy and cost intensive.

Dr. Curt Scharfe and colleagues have developed RUSPseq, a method for next generation molecular testing originally conceived to diagnose metabolic disorders in newborns.

Researchers at Stanford University have developed a rapid and sensitive bioluminescent assay for screening bacterial infections using enzyme-produced photo emission for detection of beta lactamase activity.

Stanford researchers in The Tang Group have developed a reproducible, high throughput device that dices tissue into uniformly sized sub-millimeter sample fragments.

A common hurdle for many drug delivery applications is getting the desired compounds to the targeted cells or receptors. Additional barriers of achieving the therapeutic drug concentration and necessary drug diffusion are also present even after successful targeted delivery.

Disease indication - Oncology/solid tumors, notably glioblastoma

Drug format - Engineered peptide for cancer vaccine optimization.

Drug class - Improvement to existing vaccine.

Dysregulated DNA methylation is associated with poor prognosis in cancer patients, promoting tumorigenesis and therapeutic resistance.

Stanford researchers have developed high-titer bacteriophage and annexin V formulations for rapid, more effective phage therapy against bacterial infection.

Researchers at Stanford and the Chan Zuckerberg Biohub have developed a transcriptomic characterization of human endometrium and identified specific gene signatures for use in evaluating endometrial samples for one or more menstrual cycle events.

Proliferative vitreoretinopathy (PVR) is a rare ocular condition that can lead to vision loss or blindness and is a complication of rhegmatogenous retinal detachment, severe diabetic retinopathy, and other conditions.

Physicians at Stanford Lucile Packard Children's Hospital (LPCH) have developed a novel Vesico-Amniotic Shunt (VAS) for treatment of Prenatal Lower Urinary Tract Obstruction (LUTO).